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Abolishing the inhibitory signal of intracellular cAMP is a prerequisite for effector T (Teff) cell
function. The regulation of cAMP within leukocytes critically depends on its degradation
by cyclic nucleotide phosphodiesterases (PDEs). We have previously shown that PDE8A,
a PDE isoform with 40–100-fold greater affinity for cAMP than PDE4, is selectively
expressed in Teff vs. regulatory T (Treg) cells and controls CD4+ Teff cell adhesion and
chemotaxis. Here, we determined PDE8A expression and function in CD4+ Teff cell
populations in vivo. Using magnetic bead separation to purify leukocyte populations from
the lung draining hilar lymph node (HLN) in a mouse model of ovalbumin-induced allergic
airway disease (AAD), we found by Western immunoblot and quantitative (q)RT-PCR
that PDE8A protein and gene expression are enhanced in the CD4+ T cell fraction
over the course of the acute inflammatory disease and recede at the late tolerant
non-inflammatory stage. To evaluate PDE8A as a potential drug target, we compared the
selective and combined effects of the recently characterized highly potent PDE8-selective
inhibitor PF-04957325 with the PDE4-selective inhibitor piclamilast (PICL). As previously
shown, PF-04957325 suppresses T cell adhesion to endothelial cells. In contrast, we
found that PICL alone increased firm T cell adhesion to endothelial cells by ∼20% and
significantly abrogated the inhibitory effect of PF-04957325 on T cell adhesion by over
50%when cells were co-exposed to PICL and PF-04957325. Despite its robust effect on
T cell adhesion, PF-04957325 was over two orders of magnitude less efficient than PICL
in suppressing polyclonal Teff cell proliferation, and showed no effect on cytokine gene
expression in these cells. More importantly, PDE8 inhibition did not suppress proliferation
and cytokine production of myelin-antigen reactive proinflammatory Teff cells in vivo
and in vitro. Thus, targeting PDE8 through PF-04957325 selectively regulates Teff cell
interactions with endothelial cells without marked immunosuppression of proliferation,
while PDE4 inhibition has partially opposing effects. Collectively, our data identify
PF-04957325 as a novel function-specific tool for the suppression of Teff cell adhesion
and indicate that PDE4 and PDE8 play unique and non-redundant roles in the control of
Teff cell functions.
Keywords: cyclic nucleotide phosphodiesterases (PDEs), PDE8A, PDE8 inhibitor, cAMP, T cell, adhesion, allergic
airway disease
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INTRODUCTION
The second messenger cyclic adenosine monophosphate (cAMP)
regulates a broad range of biological functions, including the
maintenance of immune tolerance (Bourne et al., 1974). cAMP
controls the immune response mainly through activation of
cAMP-dependent protein kinase A (PKA) which suppresses
activation and function of effector T (Teff) cells (Bourne et al.,
1974; Baillie et al., 2005; Sitkovsky and Ohta, 2005; Bender
and Beavo, 2006; Peter et al., 2007). Recently, we and others
have also determined a role for exchange protein activated by
cAMP (Epac) in this process (Vang et al., 2013; Almahariq et al.,
2015). Formation of site- and function-specific cAMP gradients
and spatially distinct signals within cells critically depend on
degradation by phosphodiesterases (PDEs), a family of enzymes
that hydrolyze cAMP. As a consequence of selective expression
and signaling complex formation of PDEs, cAMP signaling is
compartmentalized in cells (Baillie, 2009; Houslay, 2010; Conti
et al., 2014; Lomas and Zaccolo, 2014). This allows specific PDE
isoforms to control distinct cellular functions. Altered expression
and positioning of particular PDE isoforms may affect cell and
tissue function and lead to pathology. While PDE enzymes are
encoded by 21 different genes, 11 gene families (PDEs 1–11) are
currently noted based on sequence similarities and biochemical
properties and functions (Lerner and Epstein, 2006; Francis
et al., 2011; Azevedo et al., 2014; Maurice et al., 2014; Ahmad
et al., 2015). Several transcription initiation sites and alternative
splicing contribute to the formation of over 100 different forms
of PDEs (Lerner and Epstein, 2006; Francis et al., 2011; Azevedo
et al., 2014; Maurice et al., 2014; Ahmad et al., 2015).
Based on the unique roles of individual PDEs, selective PDE
inhibition by drugs is considered an attractive approach to
modulate cell and tissue function. Due to their importance in
governing subcellular temporal distribution of cyclic nucleotides,
and their accessibility to potent small molecule inhibitors, PDEs
make excellent drug targets, including in diseases associated
with chronic inflammation (Souness et al., 2000; Burnouf and
Pruniaux, 2002; Castro et al., 2005; Martinez and Gil, 2014).
PDE4, PDE7, and PDE8 enzymes are cAMP-specific PDEs
expressed in T cells (Lerner and Epstein, 2006). After many
years of preclinical development, two novel PDE4 inhibitors have
recently been approved for clinical use in chronic obstructive
pulmonary disease (COPD) and psoriatic arthritis (Giembycz,
2008; Spina, 2008; Tenor et al., 2011; Poole and Ballantyne, 2014;
Genovese et al., 2015). These successes prompted the preclinical
development of numerous novel PDE4 inhibitors being tested as
potential therapies in a wide range of inflammatory disorders.
Since PDEs have different expression and functional profiles in
different cell and tissues, a major goal is to selectively inhibit
additional PDE families that are expressed in T cells in the hope
that distinct and targeted therapeutic activity can be achieved
without the side effects associated with PDE4 inhibitors. Previous
studies indicated that the high affinity isoforms PDE7A and
PDE8A are required for full T cell activation (Li et al., 1999;
Glavas et al., 2001). The more recently discovered PDE8 family,
encoded by the PDE8A and PDE8B genes, is characterized by
high affinity and specificity for cAMP. As we and others have
shown, PDE8A is important in immune processes such as T
cell activation, effector T cell adhesion, and chemotaxis (Dong
et al., 2006; Vang et al., 2010, 2013) as well as breast cancer
cell motility (Dong et al., 2015). Until recently, pharmacological
approaches to studying PDE8 function have been hampered
by the lack of suitable inhibitors. Selective inhibitors of PDE8
enzymes were not available and PDE8 is insensitive to the
broadmethylxanthine based PDE inhibitors such as 3-isobutyl-1-
methylxanthine (IBMX). The broad PDE inhibitor dipyridamole
(DP) was the only compound known to inhibit PDE8 enzymes,
and its inhibition of these enzymes was somewhat weak (IC50
= 4–40 µM; Lerner and Epstein, 2006). In 2010, we were the
first to report a potent and selective PDE8 inhibitor developed by
Pfizer Inc., PF-04957325, that is now widely used to study PDE8
function in vitro and in vivo (Vang et al., 2010; Tsai et al., 2011;
Tsai and Beavo, 2012; Brown et al., 2013; Demirbas et al., 2013).
Our work showed that inhibition of PDE8 with PF-04957325
suppresses two major T cell integrins and firm attachment of
effector CD4+ T (Teff) cells to endothelial cells (Vang et al.,
2010). Further, treatment of mice with PF-04957325 in vivo
ameliorates the signs of experimental encephalomyelitis without
the side effects associated with PDE4 inhibitor treatment (Basole
and Brocke, unpublished results).
To further delineate the specific functions of PDE8 selective
inhibition in T cells and to explore the therapeutic potential of
targeting PDE8, we probed its function by direct comparison of
PDE8 inhibition to a PDE4 selective inhibitor with comparable
potency, and to analyze PDE8 expression in immune responses
in vivo utilizing a bi-phasic murine model of ovalbumin (OVA)-
induced allergic airways disease (AAD).
METHODS
Animals
Six to Twelve-week-old female C57BL/6 mice were obtained
from Jackson Laboratories (Bar Harbor). Female mice are widely
used in experimental allergy and autoimmunity models, and we
used them to keep consistency with previous studies (Reinhold
et al., 2006; Singh et al., 2008). Experiments were performed
according to approved protocols at UConn Health (IACUC
Protocol number 100794).
Bi-Phasic Model of OVA-Induced AAD
For the induction of OVA-induced AADmice were: (1) sensitized
to 25 µg OVA in the adjuvant alum with 3 intraperitoneal
injections, 1 week apart; (2) 1 week after the last immunization,
mice in each group were exposed to 1% aerosolized OVA in
physiological saline (1 h/day, 5 days a week until sacrifice)
with an estimated inhaled daily dose of 30–40 µg/mouse as
described previously (Yiamouyiannis et al., 1999; Schramm
et al., 2004; Singh et al., 2008). Groups of mice (5/group)
were sacrificed at 3, 7, and 42 days post start of daily
aerosolization. Mice sacrificed at 3 and 7 days represent AAD
(peak inflammation) and those at 42 days represent resolution
of AAD and the development of tolerance. At sacrifice, the
lung draining hilar (mediastinal) lymph node (HLN) and
peripheral inguinal lymph nodes (ILN) were dissected and
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further processed as described below. This bi-phasic model
enables us to study the expression of PDE8A during and after
acute inflammation.
Myelin Oligodendrocyte Glycoprotein
(MOG) Peptide MOG35−55
MOG35−55peptide, corresponding to mouse sequence
(MEVGWYRSPFSRVVHLYRNGK) was synthesized and
purified by the Yale University Synthesis Facility.
Immunization of Mice with
MOG35−55Peptide
Six to Twelve-week-oldmice were immunized withMOG35−55 in
Complete Freund’s Adjuvant (CFA; Sigma-Aldrich), a procedure
to induce experimental autoimmune encephalomyelitis (EAE) in
C57BL/6 mice, an animal model of multiple sclerosis (MS; Preller
et al., 2007). A total of 200 µg of MOG35−55 peptide and 400
µg of killedMycobacterium tuberculosis (Difco Laboratories) was
emulsified in CFA and injected s.c. into the footpads of mice.
Cell Isolation and Activation
In the AAD model, lymph node cells (LNC) from HLN and
ILN were processed using CD4+ T cell isolation kits (Miltenyi
Biotec) to separate CD4+ from CD4− cell populations. LNC
were also dissected from draining popliteal lymph nodes after
s.c. immunization with MOG35−−55peptide, an autoantigen
recognized by T cells in EAE and MS (Preller et al., 2007).
Concanavalin A (Con A) activated mouse splenocytes as a source
of T cell blasts were prepared and cultured as described (Dong
et al., 2006; Vang et al., 2010). Cells were either immediately
frozen in appropriate reagents for subsequent qRT-PCR or
Western immunoblot analyses or used in proliferation assays as
described (Vang et al., 2013).
RNA Isolation and cDNA Synthesis
RNA from cells was isolated using the RNeasy mini kit
and treated with Turbo DNA-free Dnase (Ambion). cDNA
was synthesized using Superscript III reverse transcriptase
(Invitrogen; Vang et al., 2010, 2013).
Quantitative Real-Time RT-PCR Analysis
Quantitative real-time RT-PCR (qRT-PCR) was performed as
described previously (Vang et al., 2010, 2013). Ten nanograms
of cDNA was amplified by qRT-PCR in a 25 µl reaction
using SYBR Green PCR Master Mix (Applied Biosystems).
Primers were designed using Primer Express software v3.0.
Primers were chosen from gene regions common to all known
splice variants of a specific gene product. Primer efficiency was
verified by slope analysis to be 100 ± 2.5%. qRT-PCR was
performed using an ABI 7500 fast system and data analyzed
using the 1ct method (SDS software v3.0). Primer sequences
and amplicon sizes were published previously (Vang et al.,
2010, 2013). Expression data were normalized by calculating
the ratio of target gene expression/housekeeping gene rpl19
expression.
Western Immunoblot Analysis
Western immunoblot analysis was performed as described
previously (Dong et al., 2010; Vang et al., 2013; Almahariq et al.,
2015). Mouse T cells were centrifuged at 300 × g for 5min,
washed twice with ice-cold PBS, and lysed in RIPA buffer with
1:100 protease inhibitor cocktail (Sigma). Protein concentration
was determined using a BCA Protein Assay Kit (Pierce). Equal
amounts of protein were loaded and run on 10% SDS-PAGE
gels. Proteins were then transferred onto Immobilon-P transfer
membrane (Millipore). Membranes were blocked with 5% BSA in
Tris-buffered saline for 1 h at room temperature and probed with
primary antibodies overnight at 4◦C. Specificity and source of
antibodies directed against PDE gene families and isoforms were
published previously (Vang et al., 2013). Additionally, a PDE8A
specific ab was obtained from Scottish Biomedical and used
at a 1:1000–1:2000 dilution on nitrocellulose membrane (Bio-
Rad) blots. After probing, membranes were washed three times
with TBS-T buffer, and incubated with horseradish peroxidase-
conjugated secondary antibody (Anti-Rabbit IgG-horseradish
peroxidase was obtained from GE Healthcare or Santa Cruz) at
a final dilution of 1:5000 and then washed three more times.
Proteins were visualized and quantitated with SuperSignal West
Femto Maximum Sensitivity Substrate (Pierce) using Syngene
G:Box with GeneSnap BioImaging software. Staining with anti-
GAPDH antibody (Abcam) was used for loading control and the
signal was used for normalization in quantitation by determining
the ratio of the target protein band density/GAPDH band
density for CD4+ cells divided by the target protein band
density/GAPDH band density for the CD4− cell population.
Adhesion Assays
Adhesion assays were performed in 24-well plates with
a confluent layer of activated cells of the murine brain
endothelium-derived cell line bEnd.3 (ATCC). 100 µM DP,
300 µM IBMX, 1 and 0.1 µM PICL, or PF-04957325 were
added to bEnd.3 cells for the last 45min of TNF-α incubation.
T cell blasts or Teff cells were labeled with 5 µM Calcein
AM (Molecular Probes) and treated as described above. 7
× 105 pretreated T cell blasts or Teff cells per well were
incubated on bEnd.3 cells in RPMI media. After 30min at
37◦C, non-adherent cells were removed by washing with D-
PBS. For analysis, 7 × 105 Calcein AM labeled T cell blasts
or Teff cells were used as positive controls. Fluorescence
was read in a Victor 3v microplate reader (Perkin Elmer)
with a fluorescein filter set. The percentage of labeled cells
resistant to detachment was calculated as total fluorescence of
well divided by fluorescence of 7 × 105 Calcein AM labeled
cells.
Proliferation Assays
Isolated Teff cells (5 × 104/well) were cultured in round
bottom 96-well plates (Costar) in the presence or absence of
soluble anti-CD3 mAb (0.7 µg/ml; R&D). PICL (1, 0.1, 0.01
µM), PF-04957325 (1, 0.1, 0.01 µM), alone or in combination,
or vehicle control (0.1% DMSO in media) were added at
0 h (Vang et al., 2013). Proliferation of popliteal LNC in
response to MOG35−55peptide with inhibitors or vehicle control
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was performed in round bottom 96-well plates (Costar) at
a concentration of 2 × 105 cells/well. After 48 h, 2 µCi
per well of [3H]thymidine (NEN) was added and cells were
harvested 16 h later using a semiautomated cell harvester.
[3H]thymidine incorporation was determined by scintillation
counting.
Statistics
Experimental groups were compared by analyzing data
with the Student’s unpaired t-test or one-way ANOVA
followed by Bonferroni t-test using SigmaStat and GraphPad
software. Probability levels for statistically significant
differences are indicated by the p-value in the figure legend
and by corresponding asterisks in the figures (∗p < 0.05,
∗∗p< 0.001).
RESULTS
Selective Expression of PDE8A in CD4+ vs.
CD4− T Cells in Inflammation In vivo
We previously determined the expression of PDE8A in Teff
and Treg cells in vitro and in vivo after challenge with antigen
(Vang et al., 2010, 2013). Of note, PDE8B expression has not
been detected in T cell populations (Hayashi et al., 1998; Dong
et al., 2006, 2010). To address the question of whether PDE8 is
a potential target for the therapeutic use of selective inhibitors
in a T cell mediated inflammatory disease, we analyzed PDE8
expression in lymph nodes of mice challenged with OVA-AAD
(Carson et al., 2008). Research over the last three decades has
provided evidence that T helper 2 (Th2) CD4+ T cells are
a major contributor to the development of AAD in animals
and asthma in humans. Using a biphasic ovalbumin (OVA)-
induced murine model of AAD (Carson et al., 2008), in which
resolution occurs with long-term continuous antigen challenge,
we separated HLN cells draining the lung tissue at different
time points after AAD induction by OVA aerosol exposure (day
3, 7, and 42) into CD4+ from CD4− fractions by magnetic
bead technique and determined the expression of PDE8A in
these cell populations by Western immunoblot. We found that
expression of PDE8A protein was higher in CD4+ T cells as
compared to the CD4− LNC population at day 7 and 42 after
AAD induction inHLN (Figures 1A,B). This was not seen in ILN
cell populations (Figures 1C,D). Collectively, these data suggest
that PDE8A protein abundance is higher in the HLN CD4+ T
cell population than in the HLN CD4− cell population at the
acute intermediate and later stage of AAD. In contrast, in both
HLN and ILN, PDE8A protein expression was lower in CD4+
T cells as compared to the CD4− LNC population at the early
acute stage of AAD on day 3 (Figure 1). Of note, this selective
expression pattern was not seen with PDE4B isoforms (data not
shown). In contrast to protein expression, the highest of pde3b,
pde4b, pde7a, and pde8a genes in the CD4+ T cell fractions from
HLN were at day 3 of AAD induction (Figure 2). Taken together,
overall expression levels of pde3b, pde4b, pde7a, and pde8a genes
were higher during the acute AAD phase (day 3 or day 7 of the
OVA challenge) than at the tolerance (day 42 of OVA challenge)
stage of the disease model.
Opposing Effects of PDE8 and PDE4
Inhibition on T Cell Adherence to
Endothelial Cells In vitro
Functionally, by using the inhibitor DP that inhibits a broad
range of PDEs including PDE8 and the recently developed potent
and highly PDE8-selective inhibitor PF-04957325 (IC50 = 0.0007
µM for PDE8A and< 0.0003 µM for PDE8B), we demonstrated
unique effects of PDE8 inhibition on adhesion and chemotaxis of
activated T cells (Vang et al., 2010). PDE4 inhibition alone was
ineffective in both assay systems. In previous experiments, we
repeatedly detected a trend of increase of T cell blast adhesion
to endothelial cells and chemotaxis when cells were treated with
the highly selective and potent PDE4-selective inhibitor PICL.
Therefore, we examined here the effect of combined inhibition
of both the PDE4 and PDE8 families which has never been
tested. As seen before, DP and PF-04957325 significantly inhibit
T cell adhesion in these assays. PF-04957325 had an inhibitory
effect on T cell blast adhesion to the endothelial cell line b.End3
by 57% and 29% at 1 µM and 0.1 µM, respectively (Figure 3)
(∗p < 0.05, ∗∗p < 0.001; one-way ANOVA and Bonferroni t-
test). Of note, DP and PF-04957325 were the only compounds
that significantly suppressed T cell adhesion. In contrast, the
broad PDE inhibitor IBMX—which does not inhibit PDE8—only
marginally suppressed adhesion of activated T cells to b.End3
cell. Importantly, PICL, a highly potent PDE4 selective inhibitor,
reversed the inhibitory effect of PF-04957325 at 1 µM from 57 to
21% when used in combination (Figure 3; ∗p < 0.05; one-way
ANOVA and Bonferroni t-test). These results clearly establish
opposing effects, including partial reversal, of PDE8 vs. PDE4
inhibition on rapid T cell adhesion in vitro, a conclusion which
is additionally supported by PICL enhancing adhesion to 21%
above the DMSO control when acting alone (Figure 3; ∗p< 0.05;
one-way ANOVA and Bonferroni t-test).
Differential Potency of PDE8 and PDE4
Inhibition on T Cell Proliferation In vitro
and Ex vivo
Our results on adhesion are notable since in proliferation
studies, PICL was significantly more efficient at suppressing
Teff cell proliferation compared to PF-04957325 indicating a
selective effect of PDE8 inhibition on rapid T cell adhesion to
endothelial cells. To further probe the selectivity of PDE8 action
in the control of T cell function, we examined the single and
combined effect of broad and selective inhibitors on purified
Teff cell proliferation in response to polyclonal or antigen-
specific stimulation through the T cell receptor (TCR) (Figure 4).
Isolated Teff cells were stimulated with immobilized anti-CD3
mAbs in the presence of broad and selective PDE inhibitors
over a range of concentrations alone and in combination in
order to establish a dose-response. The PDE4-selective inhibitor
PICL was over 100-times more effective in suppressing Teff cell
proliferation than PF-04957325 (compare 1 µMPF-04957325 vs.
0.01 µM PICL, Figure 4). There was a slight additional effect
when both inhibitors were combined, whereas the opposing
effects seen in the adhesion assays (Figure 3) were not observed
in any of the proliferation experiments (Figure 4).
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FIGURE 1 | Differential expression of PDE8A isoforms in CD4+ and CD4− leukocyte populations localized in the HLN of mice with OVA-AAD in vivo.
PDE expression was analyzed by Western immunoblot in ex vivo isolated HLN (A,B) and ILN (C,D) cells from mice with AAD. LNCs were separated into CD4+ and
CD4− populations by magnetic bead isolation. A (HLN) and C (ILN) show a comparison of PDE8A protein expression at day 3, 7, and 42 AAD between the CD4+ T
cell and CD4− leukocyte subpopulations and GAPDH as a loading control for each immunoblot. The data shown are immunoblot analyses from pooled LNCs from 5
HLN that were separated into CD4+ and CD4− populations for each day of the experiments. B (HLN) and D (ILN) show abundance of PDE8A protein determined by
immunoblot densitometry and normalized to GAPDH expression. The figure shows the mean + SEM of the quantification of results from HLN samples from days 3, 7,
and 42 AAD performed in 2 independent experiments (n = 5 mice per group, 2 groups per day, total n = 30 mice) as the ratio of the target protein band
density/GAPDH band density for CD4+ cells divided by the target protein band density/GAPDH band density for the CD4− cell population with the CD4− ratio
set at 1.
Additionally, we tested in vitro recall stimulation of T cells
from lymph nodes of mice immunized with an encephalitogenic
peptide, MOG35−55,of the myelin antigen MOG which is an
autoantigen in EAE and MS (Brocke et al., 1996; Preller et al.,
2007). In these assays, in contrast to experiments with anti-
CD3 stimulation, antigen presenting cells are present during
the entire experiment. As shown in Figure 5, proliferation was
not inhibited by PF-04957325 application in vivo (Figure 5A)
or in vitro (Figure 5B). In contrast, PICL profoundly inhibited
the proliferation in response to MOG35−55 in vitro (Figure 5B),
similar to the effect seen in anti-CD3 responses (Figure 4).
DISCUSSION
PDE enzymes are highly successful drug targets for treating
vascular and inflammatory diseases (Martinez and Gil, 2014;
Maurice et al., 2014). The ability to form site- and function-
specific cAMP gradients within the cell critically depends on its
degradation by PDEs which are pivotal regulators of intracellular
cAMP activity (Baillie, 2009; Houslay, 2010; Conti et al., 2014;
Lomas and Zaccolo, 2014). Observations that inhibition of
PDE4, an abundantly expressed PDE in T cells, blocks T cell
activation and function through elevating cAMP, prompted the
development of PDE4 inhibitors as potential immunosuppressive
therapies (Ekholm et al., 1997; Lerner and Epstein, 2006; Lugnier,
2006; Giembycz, 2008; Spina, 2008). After years of research
and development of numerous candidate compounds, the FDA
approval of the PDE4 inhibitors roflumilast and apremilast in
2011 and 2014 for the treatment of COPD and psoriatic arthritis
represent important breakthroughs for the use of PDE inhibitors
in the therapy of human inflammatory disorders. Due to the
limitations of PDE4 inhibitors set by their narrow therapeutic
window, several alternative strategies are pursued to target PDEs
in immune diseases. These include the inhibition of different
cAMP-specific PDEs, such as PDE7 and PDE8. The recent
development of the new PDE8 inhibitor PF-04957325 has helped
to identify PDE8 as a novel target for suppression of effector T
cell functions due to the important role of the PDE8 family in
regulating cAMP signaling in these cells (Martinez andGil, 2014).
After the initial observation that PDE8A is expressed in T cells,
several reports documented the role of PDE8 in controlling T cell
and cancer cell motility (Glavas et al., 2001; Dong et al., 2006,
2015; Vang et al., 2010, 2013). Together, PDE7 and PDE8 are now
seen as new emerging targets to treat inflammation (Martinez and
Gil, 2014). Our data demonstrate for the first time robust PDE8A
expression in leukocytes associated with an inflammatory disease
in vivo, a mouse model of AAD. The preferential expression
of PDE8A protein in the CD4+ T cell subset during the acute
AAD stage and its subsequent recession in the non-inflammatory
tolerant stage, together with the common assumption that CD4+
Teff cells are a major contributor to the development of AAD in
animals and asthma in humans, strengthen the case to further
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FIGURE 2 | Pde3b, pde4b, pde7a, and pde8a gene expression in CD4+ T cells localized in the draining HLN of mice at various days of OVA exposure in
vivo. PDEs were analyzed by qRT-PCR in ex vivo isolated HLN cells from mice with AAD separated into CD4+ and CD4− cell populations. Data are normalized and
expressed as the ratio mean + SEM of target gene expression/housekeeping gene rpl19 expression. Data in (A) show a comparison of pde3b gene expression in
CD4+ cells of HLN samples from days 3, 7, and 42 AAD (n = 3). Data in (B) show pde4b gene expression, in (C) pde7a gene expression and in (D) expression of
pde8a in CD4+ cells of HLN in AAD. (n = 5 mice per group, total n = 15 mice; *p < 0.05, **p < 0.001, unpaired t-test).
examine PDE8A inhibition in preclinical and clinical studies
of inflammatory disorders, including human respiratory airway
diseases.
Previously, we failed to detect any suppressive effect of the
highly potent PDE4-selective inhibitor PICL on T cell adhesion
to activated endothelial cells. In contrast, DP reduced adhesion
of T cell blasts by 73% while PF-04957325 reduced adhesion by
a maximum of 53%. However, PICL was also very efficient at
suppressing proliferation. Thus, our data suggest that a rapid
effect on T cell adhesion critically depends on a PDE inhibitor
that blocks PDE8 enzymatic activity, while inhibition of Teff cell
proliferation is less dependent on blocking the PDE8 isoform.
In this present study, we explored the precise action of PDE8
and PDE4 selective inhibition of T cell adhesion by testing
inhibitors over a range of concentrations and in combination. In
doing so, we found an entirely novel effect of PDE4 inhibition
enhancing adhesion of T cells to endothelial cells and opposing
the inhibitory effect of PDE8 inhibition. These data suggest
distinct signaling pathways utilized by PDE8 and PDE4 in T
cells, a hypothesis further supported by the differential action of
selective inhibitors of these enzymes in proliferation assays.
At present, it is unknown what accounts for the different
effects of selected PDE isoform inhibition during adhesion
and proliferation. Regulation of adhesion of leukocytes to
vascular endothelial ligands is a very fast process measured in
microseconds (Grabovsky et al., 2000). A possible mechanism
may be that DP and PF-04957325 upregulate intracellular cAMP
levels more rapidly and efficiently than PDE inhibitors that
do not block PDE8, requiring a longer time of action for less
efficient PDE inhibitors during Teff cell adhesion (Zhuplatov
et al., 2006). Since PDE8A is a very high affinity cAMP-specific
PDE with a Km value ranging from 0.04 to 0.15µM, 40–100
times lower than that of PDE4, it is likely to be functioning at
lower cAMP concentrations than PDE4 andmay thus be involved
in the control of intracellular cAMP concentrations at basal levels
and in the immediate response to acute increases of cAMP in
specific cell regions (Fisher et al., 1998; Soderling et al., 1998;
Vasta, 2007). This mechanism would be consistent with our data.
Major mechanistic insights into PDE8A signaling came from a
recent report that PDE8A associates with Raf-1 to protect it from
inhibitory phosphorylation by PKA (Brown et al., 2013). Raf
kinases have been shown to regulate integrin α4β1-mediated T
cell resistance to shear stress which may explain our observations
in T cell adhesion assays (Brown et al., 2014).
We also analyzed the effects of PF-04957325 administration
on CD4+ responses in draining lymph nodes 10 days after
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FIGURE 3 | Inhibiting PDE8 suppresses Teff cell adhesion to endothelial
cells and is reversed by PDE4 inhibition. T cell blasts from C57BL/6 mice
and bEnd.3 endothelial cells were incubated alone or in combination with IBMX
(300 µM), PICL (1 or 0.1 µM), DP (100 µM) or PF-04957325 (1 or 0.1 µM).
Values are normalized to the vehicle condition (0.1% DMSO) and presented as
the mean ± SEM percentage of T cell blasts resistant to detachment. Data are
averages from three to four independent experiments performed in triplicate
(*p < 0.05, **p < 0.001, one-way ANOVA and Bonferroni t-test).
FIGURE 4 | Selective inhibition of Teff cell proliferation by PDE4
inhibition in vitro. Proliferation of purified CD4+CD25− Teff cells exposed to
PDE inhibitors. Teff cells (5 × 104/well) were cultured with immobilized
anti-CD3 mAb or control in the presence of IBMX (300 µM), DP (100 µM),
PICL, PF-04957325 alone or in combination, or vehicle control (0.1% DMSO).
The extent of proliferation was determined by [3H]thymidine incorporation at
64 h and results are presented as mean + SEM counts per min (cpm). Data
are representative of three to five independent experiments performed in
triplicate (*p < 0.05, **p < 0.001, comparisons to vehicle were analyzed using
a one-way ANOVA and Bonferroni t-test).
MOG35−55 and CFA immunization. We found no effect of
PF-04957325 administered s.c. on CD4+ Teff cell proliferation
(Figure 5) or production of IFNγ or IL-17, nor changes in
FIGURE 5 | PF-04957325 does not suppress T cell proliferation in
response to MOG35−55 ex vivo and in vitro.(A) C57BL/6 mice were
immunized with MOG35−55 and CFA and treated twice daily from days 8 to 10
by subcutaneous administration of PF-04957325 (PF1, PF2) or vehicle control
(V1, V2) (n = 2 mice per group, total n = 4). Each injection contained a dose of
2.5 mg/kg PF-04957325 dissolved in 100µl vehicle (PF-04957325) or 100µl
vehicle alone (vehicle control). (B). C57BL/6 mice were immunized with
MOG35−55 and CFA (n = 2). (A,B) Draining popliteal lymph nodes were
dissected 10 day after immunization and an in vitro proliferation assay was
performed under conditions as indicated. MOG35−55 (50µg/ml) was present
where indicated (A,B), together with PDE inhibitors in vitro as shown (B).
percentage and numbers of CD4+, Foxp3+ (Treg cells), γδTCR+
or Ki-67+ (proliferating) T cells in the draining lymph nodes
of CFA and MOG35−55 immunized mice (data not shown).
Additionally, in contrast to the PDE4-selective inhibitor PICL,
PF-04957325 did not significantly suppress T cell proliferation
in vitro in response to MOG35−55 and showed over 100-times
lower efficacy in suppressing proliferative responses to anti-CD3
stimulation. The different potency of PF-04957325 in assays
using whole lymph nodes could indicate a role for costimulation
provided by antigen-presenting cells overcoming its moderate
anti-proliferative action when isolated Teff cell proliferation were
stimulated by anti-CD3 mAb. Overall, our results indicate a
non-redundant role for PDE8 in regulating T cell adhesion
to vascular endothelium through the cAMP signaling pathway.
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The data further suggest that PDE8 inhibition, if successful in
vivo in inflammatory diseases, may selectively target leukocyte
motility without exerting global immunosuppressive effects on
cytokine production and cell proliferation and thus provide a
highly selective therapeutic tool while maintaining the proven
characteristics of PDE inhibitors as successful drugs. Taken
together, efforts to develop and test selective inhibitors of PDE8
such as PF-04957325 should be undertaken as a means to develop
novel therapeutic agents for treatment of inflammatory disorders
mediated by activated T cells (Steinman, 1996, 2004; Ford et al.,
2003; Ransohoff, 2007; Li and Ransohoff, 2008).
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